Evidence map›Paper›PMID 27421245›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2016

HBX Protein-Induced Downregulation of microRNA-18a is Responsible for Upregulation of Connective Tissue Growth Factor in HBV Infection-Associated Hepatocarcinoma.

Xiaomin Liu, Yingjian Zhang, Ping Wang, Hongyun Wang, Huanhuan Su, Xin Zhou, Lamei Zhang

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Xiaomin LiuDepartment of Gastroenterology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China (mainland).
Yingjian ZhangDepartment of Gastroenterology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China (mainland).
Ping WangDepartment of Public Health, School of Medicine, Henan University of Science and Technology, Luoyang, Henan, China (mainland).
Hongyun WangDepartment of Gastroenterology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China (mainland).
Huanhuan SuDepartment of Gastroenterology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China (mainland).
Xin ZhouDepartment of Gastroenterology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China (mainland).
Lamei ZhangDepartment of Gastroenterology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China (mainland).
First Affiliated Hospital of Henan University of Science and Technology · CNHenan University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND This study was designed to improve our understanding of the role of miR-18a and its target (connective tissue growth factor (CTGF), which are mediators in HBX-induced hepatocellular carcinoma (HCC). MATERIAL AND METHODS We first investigated the expression of several candidate microRNAs (miRNAs) reported to have been aberrantly expressed between HepG2 and HepG2.2.15, which is characterized by stable HBV infection, while the CTGF is identified as a target of miR-18a. Furthermore, the expression of CTGF evaluated in HepG2 was transfected with HBX, while the HepG2.2.15 was transfected with miR-18a and CTGF siRNA. We examined the cell cycle at the same time. RESULTS We found that the expression of miR-18a was abnormally reduced in the HBV-positive HCC tissue samples compared with HBV-negative HCC samples. Through the use of a luciferase reporter system, we also identified CTGF 3'UTR (1046-1052 bp) as the exact binding site for miR-18a. We also observed a clear increase in CTGF mRNA and protein expression levels in HBV-positive HCC human tissue samples in comparison with the HBV-negative controls, indicating a possible negatively associated relationship between miR-18a and CTGF. Furthermore, we investigated the effect of HBX overexpression on miR-18a and CTGF, as well as the viability and cell cycle status of HepG2 cells. In addition, we found that HBX introduction downregulated miR-18a, upregulated CTGF, elevated the viability, and promoted cell cycle progression. We transfected HepG2.2.15 with miR-18a mimics and CTGF siRNA, finding that upregulated miR-18a and downregulated CTGF suppress the viability and cause cell cycle arrest. CONCLUSIONS Our study shows the role of the CTGF gene as a target of miR-18a, and identifies the function of HBV/HBX/miR-18a/CTGF as a key signaling pathway mediating HBV infection-induced HCC.

Indexed as

Carcinoma, HepatocellularCase-Control StudiesCell Cycle CheckpointsCell Line, TumorConnective Tissue Growth FactorDown-RegulationHepatitis B, ChronicHepatitis B virusHep G2 CellsHumansLiver NeoplasmsMicroRNAsRNA, MessengerRNA, Small InterferingSignal TransductionTrans-ActivatorsCCN2 protein, humanConnective Tissue Growth Factorhepatitis B virus X proteinMicroRNAsMIRN18A microRNA, humanRNA, MessengerRNA, Small InterferingTrans-ActivatorsViral Regulatory and Accessory Proteins

Identifiers

PMID27421245
PMCPMC4959457
OpenAlexW2468657104

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.